197 related articles for article (PubMed ID: 930746)
1. CNS compensation to dopamine neuron loss in Parkinson's disease.
Lloyd KG
Adv Exp Med Biol; 1977; 90():255-66. PubMed ID: 930746
[TBL] [Abstract][Full Text] [Related]
2. [Biochemical bases of Parkinson disease].
Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
[No Abstract] [Full Text] [Related]
3. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease.
Piggott MA; Perry EK; Marshall EF; McKeith IG; Johnson M; Melrose HL; Court JA; Lloyd S; Fairbairn A; Brown A; Thompson P; Perry RH
Biol Psychiatry; 1998 Oct; 44(8):765-74. PubMed ID: 9798081
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease: from brain homogenate to treatment.
Hornykiewicz O
Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
[No Abstract] [Full Text] [Related]
5. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
6. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
7. Effect of vitamin B-6 nutrition on the levels of dopamine, dopamine metabolites, dopa decarboxylase activity, tyrosine, and GABA in the developing rat corpus striatum.
Guilarte TR
Neurochem Res; 1989 Jun; 14(6):571-8. PubMed ID: 2761676
[TBL] [Abstract][Full Text] [Related]
8. [Neurochemical aspects of parkinsonism. Review of the literature].
De Mattos JP; Cechela C; Adams JG; De Lima JM
Arq Neuropsiquiatr; 1982 Sep; 40(3):289-95. PubMed ID: 6130754
[TBL] [Abstract][Full Text] [Related]
9. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems.
Zhou FM; Wilson C; Dani JA
Neuroscientist; 2003 Feb; 9(1):23-36. PubMed ID: 12580337
[TBL] [Abstract][Full Text] [Related]
10. In vivo vulnerability of dopamine neurons to inhibition of energy metabolism.
Zeevalk GD; Manzino L; Hoppe J; Sonsalla P
Eur J Pharmacol; 1997 Feb; 320(2-3):111-9. PubMed ID: 9059843
[TBL] [Abstract][Full Text] [Related]
11. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA
Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803
[TBL] [Abstract][Full Text] [Related]
13. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
14. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat.
González-Hernández T; Barroso-Chinea P; Rodríguez M
Mov Disord; 2004 Sep; 19(9):1029-1042. PubMed ID: 15372592
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
16. Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling.
Lemos JC; Friend DM; Kaplan AR; Shin JH; Rubinstein M; Kravitz AV; Alvarez VA
Neuron; 2016 May; 90(4):824-38. PubMed ID: 27196975
[TBL] [Abstract][Full Text] [Related]
17. Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioral changes.
Bak IJ; Hassler R; Kim JS; Kataoka K
J Neural Transm; 1972; 33(1):45-61. PubMed ID: 4674484
[No Abstract] [Full Text] [Related]
18. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
[TBL] [Abstract][Full Text] [Related]
19. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
20. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
Anglade P; Tsuji S; Javoy-Agid F; Agid Y; Hirsch EC
Ann Neurol; 1995 Feb; 37(2):265-72. PubMed ID: 7847868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
